已发表论文

米诺环素的特性及其对精神分裂症的治疗潜力

 

Authors Zhang L, Zhao J

Published Date June 2014 Volume 2014:10 Pages 1103—1111

DOI http://dx.doi.org/10.2147/NDT.S64236

Received 17 March 2014, Accepted 22 April 2014, Published 17 June 2014

Abstract: Accumulating evidence suggests that neuroinflammation affecting microglia plays an important role in the etiology of schizophrenia, and appropriate control of microglial activation may be a promising therapeutic strategy for schizophrenia. Minocycline, a second-generation tetracycline that inhibits microglial activation, has been shown to have a neuroprotective effect in various models of neurodegenerative disease, including anti-inflammatory, antioxidant, and antiapoptotic properties, and an ability to modulate glutamate-induced excitotoxicity. Given that these mechanisms overlap with neuropathologic pathways, minocycline may have a potential role in the adjuvant treatment of schizophrenia, and improve its negative symptoms. Here, we review the relevant studies of minocycline, ranging from preclinical research to human clinical trials.
Keywords: schizophrenia, minocycline, microglia, neuroinflammation